¥2,485.50
0.26%
Tokyo, Nov 18, 03:16 pm JST. Closed.
ISIN
JP3197600004
Symbol
4528

Ono Pharmaceutical Stock price

¥2,489.00
+53.50 2.20% 1M
+47.50 1.95% 6M
+316.50 14.57% YTD
+481.50 23.99% 1Y
-262.50 9.54% 3Y
+39.00 1.59% 5Y
-173.50 6.52% 10Y
+1,363.93 121.23% 20Y
Tokyo, Closing price Wed, Nov 18 2026
-3.00 0.12%
ISIN
JP3197600004
Symbol
4528
Industry

AI Insights on Ono Pharmaceutical Insights AI Insights on Ono Pharmaceutical

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Ono Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
¥1.2t
Enterprise Value
¥1.0t
Net debt
positive
Cash
¥259.8b
Shares outstanding
470.1m
Valuation
P/E
15.7
P/S | estimate
2.4 | 2.5
EV/Sales | estimate
2.1 | 2.2
EV/FCF | ex SBC
8.5 | -
P/B
1.3
Dividends
DPS
¥80.00
Yield 1Y | 5Y
3.2% | 3.2%
Growth 1Y | 5Y
0.0% | 7.4%
Payout 1Y | 3Y
53.9% | 46.0%
Increased
0 Years
Financials
Revenue | estimate
¥491.2b | ¥462.7b
EBITDA
¥135.3b
EBIT
¥98.1b
Net Income
¥74.6b
Free Cash Flow | ex SBC
¥120.7b | -
Growth
Revenue | estimate
-2.5% | -10.3%
EBITDA
46.5%
EBIT
75.3%
Net Income
53.8%
Free Cash Flow
146.1%
Margin
Gross
74.1%
EBITDA
27.6%
EBIT
20.0%
Net
15.2%
Free Cash Flow | ex SBC
24.6% | -
Financial Health
Equity Ratio
76.9%
Return on Equity
8.2%
ROCE
10.3%
ROIC
10.1%
Debt/Equity
0.1
More
EPS
¥158.7
FCF per Share
¥256.8
Short interest
-
Employees
4k
Rev per Employee
¥120.3m

Ono Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Ono Pharmaceutical forecast:

3x Buy
15%
10x Hold
50%
7x Sell
35%

Analyst Opinions

20 Analysts have issued a Ono Pharmaceutical forecast:

Buy
15%
Hold
50%
Sell
35%

Ono Pharmaceutical Events

Past Events
JAN
14
44th Annual J.P. Morgan Healthcare Conference
10 months ago

Financial data from Ono Pharmaceutical

Sep '26
+/-
%
491,153 491,153
2% 2%
100%
- Direct Costs 127,170 127,170
22% 22%
26%
363,983 363,983
7% 7%
74%
- Selling and Administrative Expenses 110,444 110,444
14% 14%
22%
- Research and Development Expense 145,115 145,115
5% 5%
30%
135,329 135,329
46% 46%
28%
- Depreciation and Amortization 37,255 37,255
2% 2%
8%
EBIT (Operating Income) EBIT 98,074 98,074
75% 75%
20%
Net Profit 74,608 74,608
54% 54%
15%

In millions JPY.

Don't miss a Thing! We will send you all news about Ono Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ono Pharmaceutical Stock News

Neutral
Business Wire
●
20 days ago
OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that ONO-1110, an endocannabinoid modulator, demonstrated efficacy signals in Phase 2 clinical studies in postherpetic neuralgia (PHN), fibromyalgia (FM), and Hunner-type interstitial cystitis (HIC). Additional Phase 2 clinical studies of ONO-1110 wer...
Neutral
Business Wire
●
3 months ago
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that it has entered into a drug discovery partnership agreement with Aitia, Inc. (Headquarters: Cambridge, Massachusetts, USA; CEO: Colin Hill; “Aitia”). Under the terms of the agreement, Aitia will utilize its REFS™ technology to b...
Neutral
Business Wire
●
3 months ago
OSAKA, Japan & BOSTON--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) announced today that it has entered into a drug discovery partnership and option agreement with Mediar Therapeutics, Inc. (Headquarters: Boston, Massachusetts, USA; CEO: Rahul Ballal, PhD; “Mediar”), a clinical-stage biotechnology company specializing in fib...

Company Profile

Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.

Head office Japan
CEO Mr. Sagara
Employees 4,287
Founded 1947
Website www.ono-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today